Comments
Shares of Aurobindo Pharmaceuicals jumped 12 per cent in early trade on Tuesday to ₹605.50 on US drug regulator observation.
"Further to our intimations dated 13th November 2019, 19th February and 21st February 2020 with regard to the inspection of Unit IV, an injectable manufacturing formulation facility of the Company, conducted between Nov 4-13, 2019, we would like to inform that US FDA has determined that the inspection classification of this facility is Voluntary Action Indicated," Aurobindo Pharma said in a release to the stock exchanges.
A VAI inspection classification indicates that, although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.